# TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

> **NCT06251544** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 27 (estimated)

## Conditions studied

- Breast Cancer
- Tumor, Breast
- Breast Tumor
- Malignant Neoplasm of Breast
- Mammary Cancer
- Mammary Neoplasm
- Mammary Neoplasms, Human
- Neoplasm, Breast

## Interventions

- **GENETIC:** HTR2 T Cells
- **GENETIC:** HTR2 T Cells

## Key facts

- **NCT ID:** NCT06251544
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-01
- **Final completion:** 2044-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06251544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06251544, "TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06251544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*